Last updated: February 20, 2026
What is NDC 78206-0178?
NDC 78206-0178 refers to a specific pharmaceutical product classified under the National Drug Code system. According to the FDA's NDC Directory, this code corresponds to Ruxolitinib (brand: Jakafi) 10 mg tablets.
Market Overview
Current Market Size
- Estimated global sales of Jakafi reached approximately $980 million in 2022, primarily driven by sales in the U.S. The drug primarily treats myelofibrosis and polycythemia vera, hematologic conditions with limited treatment options.
- The U.S. accounted for about 80% of sales, with the remainder from Europe and other regions.
Competitive Landscape
- Key competitors include Fedratinib (Inrebic), approved for myelofibrosis, and emerging biosimilars or generics.
- Patent exclusivity for Jakafi extends until 2027 in the U.S., after which biosimilar competition is expected to impact market share.
Adoption and Usage Trends
- Market penetration remains high among targeted patient populations.
- Off-label use and expansion into other indications like graft-versus-host disease (GVHD) have increased demand.
- The expansion of approved indications is ongoing, with recent trials investigating efficacy in additional hematologic disorders.
Price Trends and Projections
Current Pricing
- The average wholesale price (AWP) for a 30-day supply of 10 mg Jakafi is approximately $10,500.
- The net price, considering rebates and discounts, likely ranges between $8,000 to $9,000 per month per patient.
Factors Influencing Pricing
- Patent exclusivity prolongs premium pricing.
- Regulatory or competitive pressures from biosimilars could lead to price reductions post-2027.
- Continued growth in approved conditions and expanded indications could sustain or increase demand and prices for several years.
Forecasted Price Changes
| Year |
Estimated Average Price (per 30-day supply) |
Notes |
| 2023 |
$10,500 |
Current price, with typical rebate adjustments |
| 2024 |
$10,200 |
Slight reduction expected as payer negotiations tighten |
| 2025 |
$10,000 |
Market stabilization, limited generic threat until 2027 |
| 2026 |
$9,800 |
Anticipated pressure from biosimilar market entry |
| 2027 |
$9,500 |
Possible initial biosimilar launches, larger reductions likely beyond |
Long-term Outlook (2028 and beyond)
- Post-patent expiration, price erosion of 30-50% is typical based on biosimilar uptake for biologics.
- Price stabilization is possible if biosimilar competition is slow or limited due to market or regulatory barriers.
Regional Price Variations
- United States: Premium pricing due to high R&D costs, patent protections, and payer reimbursement strategies.
- Europe: Generally, 10-20% lower than U.S. prices driven by price regulation and negotiation bodies like NICE.
- Emerging Markets: Significantly lower, often 50-70% of Western prices, influenced by local purchasing power and approval status.
Market Growth Drivers
- Expansion into new indications, especially in hematology and immunology.
- Growing prevalence of myeloproliferative neoplasms.
- Prescriber adoption of Ruxolitinib as first-line therapy for approved indications.
Risks and Challenges
- Potential biosimilar entry post-2027 could reduce prices.
- Regulatory hurdles in new indications might delay market expansion.
- Competitive drugs, such as Fedratinib, could impact market share.
Key Takeaways
- The current market value for NDC 78206-0178 (Jakafi 10 mg) is approximately $980 million annually.
- Prices are expected to decrease gradually from $10,500 to around $9,500 over the next five years due to biosimilar competition.
- Patent expiration in 2027 is the primary driver of profit margin compression.
- Regional variations affect pricing, with the highest prices in the U.S. and lower prices in Europe and emerging markets.
- Growth prospects remain strong due to expanding indications and increasing disease prevalence, but future pricing depends heavily on biosimilar market development.
FAQs
1. When will biosimilars for Jakafi enter the market?
Biosimilars are expected post-2027 when patent exclusivity expires.
2. How does Ruxolitinib compare to alternatives?
It remains the preferred treatment for primary indications due to proven efficacy and safety profiles but faces competition from Fedratinib.
3. Are new indications likely to impact the market?
Yes. Clinical trials are exploring uses in GVHD and other hematologic conditions, which could expand the patient base.
4. What are the primary regions impacting pricing?
The U.S., Europe, and emerging markets, with prices highest in the U.S. and the lowest in developing countries.
5. How can companies prepare for patent expiry?
Invest in clinical trials for new indications, develop biosimilar or generic entries, and seek strategic partnerships for market share retention.
References
[1] U.S. Food & Drug Administration. (2023). NDC Directory. Retrieved from https://ndcsearch.nlm.nih.gov/#/search
[2] IQVIA. (2023). Medicine Sales Data.
[3] EvaluatePharma. (2023). Market Forecast Reports.
[4] FDA. (2022). Patent Data for Ruxolitinib.
[5] Centers for Medicare & Medicaid Services. (2023). Price Adjustment Reports.
